ID: ALA5188822

Max Phase: Preclinical

Molecular Formula: C21H17FN4O

Molecular Weight: 360.39

Associated Items:

Representations

Canonical SMILES:  Cc1nn(-c2ccccc2F)c(C)c1C(=O)Nc1ccc2ccccc2n1

Standard InChI:  InChI=1S/C21H17FN4O/c1-13-20(14(2)26(25-13)18-10-6-4-8-16(18)22)21(27)24-19-12-11-15-7-3-5-9-17(15)23-19/h3-12H,1-2H3,(H,23,24,27)

Standard InChI Key:  CZCMXBNEWZRNEL-UHFFFAOYSA-N

Associated Targets(Human)

Protein Wnt-3a 90 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 360.39Molecular Weight (Monoisotopic): 360.1386AlogP: 4.43#Rotatable Bonds: 3
Polar Surface Area: 59.81Molecular Species: NEUTRALHBA: 4HBD: 1
#RO5 Violations: 0HBA (Lipinski): 5HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 2.34CX LogP: 4.38CX LogD: 4.38
Aromatic Rings: 4Heavy Atoms: 27QED Weighted: 0.59Np Likeness Score: -2.07

References

1. Ai Y, Sakamuru S, Imler G, Xia M, Xue F..  (2022)  Improving the solubility and antileukemia activity of Wnt/β-catenin signaling inhibitors by disrupting molecular planarity.,  69  [PMID:35777269] [10.1016/j.bmc.2022.116890]

Source